UNSPSC 85813913: Introduction of monoclonal antibody into muscle, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into muscle, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0230M

UNSPSC 85813913, Introduction of monoclonal antibody into muscle, percutaneous approach, is a Commodity code that in state and local procurement contexts shows virtually no recent activity aligned with its clinical-procedural scope. The code describes a specific medical intervention—intramuscular monoclonal antibody administration—yet the recent opportunities tagged to this code encompass telehealth urgent care, PACE operations, occupational health screening, employee wellness platforms, EMS billing, and inmate health services. State and local buyers do not procure monoclonal antibody injections as standalone line items; the code appears systematically misaligned with how state and local government actually tags health service purchases.

The mismatch between code taxonomy and actual procurement suggests this Commodity code carries limited signal for business development. Recent opportunities instead cluster around broader healthcare service categories—primary care delivery, behavioral health integration, occupational health services, employee wellness administration, and specialized clinical services like radiology reads and cancer screening—none of which map cleanly to a specific drug-delivery procedure. The handful of postings (Nevada PACE, Colorado nursing home beds, Texas HHSC radiology reads, and occupational health RFPs across multiple counties) appear incidentally tagged with this code rather than intentionally procured for monoclonal antibody administration. No state health department, county medical system, hospital authority, or school district in the recent record is actively soliciting monoclonal antibody infusion services as a standalone or primary procurement objective. Unless your firm operates clinically as a monoclonal antibody provider or repackages such services within integrated behavioral health or occupational medicine contracts, this code shows little actionable pipeline activity in state and local markets right now.